History
# Registration date Revision Id
3 2020-08-01, 1399/05/11 145589
2 2019-09-13, 1398/06/22 104168
1 2017-11-20, 1396/08/29 26061
Changes made to previous revision
  • Help:

    Red color represents old content. It may be empty showing addition in the new version.
    Green color represents new content. It may be empty showing deletion in the new version.

    Inline Side by side
    Added new contents, deleted old contents, contents that are not changed.
    New table contents New table contents
    Old table contents Old table contents
    Unchanged contents Unchanged contents
    Added new contents, contents that are not changed.
    Deleted old contents, contents that are not changed.
    Old table contents Old table contents
    Unchanged contents Unchanged contents
    New table contents New table contents
    Unchanged contents Unchanged contents
  • Protocol summary

    Objective: The aim of this study is to determine the effects of magnesium supplementation on carotid intima-media thickness (CIMT) and metabolic profiles in diabetic hemodialysis patients. Study design: Parallel double-blind (both patients and researchers) clinical trial. Randomization will be done by the use of computer-generated random numbers. Inclusion criteria: Diabetic hemodialysis patients aged 18 to 80 years will be included in the study. Exclusion criteria: Unwillingness to cooperate. Population and sample size: Among diabetic hemodialysis patients referred to Akhavan Clinic affiliated to Kashan University of Medical Sciences, 60 patients will be selected according to inclusion and exclusion criteria. Intervention: Patients will be assigned into two groups to receive magnesium supplement (n=30) or placebo (n=30). Supplements and placebos are similar in shape and size. CIMT will be determined at baseline and after 24 weeks intervention. Fasting blood samples will be taken at baseline and 24 weeks after the intervention. At the beginning and end of the intervention: 24 weeks. Outcomes: Carotid intima-media thickness (primary outcome) and metabolic profiles (secondary outcomes) will be quantified at study baseline and end-of-trial.
    empty
    هدف: هدف این مطالعه تعیین اثرات مکمل یاری منیزیم بر ضخامت اینتیما-مدیای شریان کاروتید و پروفایل های متابولیک در بیماران همودیالیزی دیابتیک است. طراحي انجام مطالعه: کارآزمایی بالینی دو سوکور (هم بیماران و هم محققان) موازی. تصادفی سازی با استفاده ازجدول اعداد تصادفی ایجاد شده توسط کامپیوتر انجام خواهد شد. معیار ورود به مطالعه: بیماران همودیالیزی دیابتیک در محدوده سنی 18 تا 80 سال وارد مطالعه خواهند شد. معیار خروج از مطالعه: عدم تمایل به همکاری. حجم نمونه و جمعیت مورد مطالعه: 60 بیمار همودیالیزی دیابتیک واجد شرایط و ارجاع شده به کلینیک اخوان وابسته به دانشگاه علوم پزشکی کاشان در مطالعه انتخاب خواهند شد. مداخله مورد مطالعه: بیماران به دو گروه برای دریافت ترکیب مکمل یاری منیزیم (30=n) یا پلاسبو (30=n) اختصاص داده خواهند شد. قرص های منیزیم با پلاسبو از نظر شکل و اندازه مشابه هستند. ضخامت اینتیما-مدیای کاروتید در ابتدا و 24 هفته بعد از مداخله تعیین خواهد شد. نمونه خون ناشتا در ابتدای مطالعه و 24 هفته بعد از مداخله از بیماران گرفته خواهد شد. زمان مداخله: 24 هفته. پيامدها: ضخامت انتیما-مدیای شریان کاروتید (پیامد اولیه) و پروفایل های متابولیک (پیامدهای ثانویه) در ابتدا و انتهای مداخله اندازه گیری خواهد شد.
    empty
    empty
    Objective: The aim of this study is to determine the effects of magnesium supplementation on carotid intima-media thickness (CIMT) and metabolic profiles in diabetic hemodialysis patients.
    empty
    هدف: هدف این مطالعه تعیین اثرات مکمل یاری منیزیم بر ضخامت اینتیما-مدیای شریان کاروتید و پروفایل های متابولیک در بیماران همودیالیزی دیابتیک است.
    empty
    Study design: randomized double-blind placebo-controlled trial. Randomization will be done by the use of computer-generated random numbers. Patients will be assigned into two groups to receive magnesium supplement (n=30) or placebo (n=30).
    empty
    طراحي انجام مطالعه: کارآزمایی بالینی دو سوکور کنترل شده با دارونما. تصادفی سازی با استفاده از جدول اعداد تصادفی ایجاد شده توسط کامپیوتر انجام خواهد شد. بیماران به دو گروه برای دریافت مکمل منیزیم (30=n) یا پلاسبو (30=n) اختصاص داده خواهند شد.
    empty
    Among diabetic hemodialysis patients referred to Yasrebi Clinic affiliated to Kashan University of Medical Sciences, Kashan, Iran, 60 patients will be selected according to inclusion and exclusion criteria. Participants, investigators or the assessors of the outcomes are unaware of the study groups. Supplements and placebos are similar in shape and size. Fasting blood samples will be taken at baseline and 24 weeks after the intervention. At the beginning and the end of the intervention: 24 weeks.
    empty
    از بین بیماران همودیالیزی دیابتیک ارجاع شده به کلینیک یثربی وابسته به دانشگاه علوم پزشکی کاشان، کاشان، ایران، 60 بیمار بر اساس معیار های ورود و خروج از مطالعه انتخاب خواهند شد. شرکت کنندگان و هم محققان یا ارزیابان پیامد از تخصیص گروههای مطالعه بی اطلاعند. کپسول های مکمل و پلاسبو از نظر شکل و اندازه مشابه هستند. نمونه خون ناشتا در ابتدای مطالعه و 24 هفته بعد از مداخله از بیماران گرفته خواهد شد. زمان مداخله: 24 هفته.
    empty
    Inclusion criteria: Diabetic hemodialysis patients aged 18 to 80 years will be included in the study.Exclusion criteria: Patients with inflammatory and malignant diseases, taking magnesium supplements, antioxidant and/or anti-inflammatory supplements within 3 months prior to enrollment in the study, taking immunosuppressive agents
    empty
    معیار ورود به مطالعه: بیماران همودیالیزی دیابتیک در محدوده سنی 18 تا 80 سال وارد مطالعه خواهند شد. معیار خروج از مطالعه: بیماران مبتلا به بیماری های بدخیم و التهابی، گرفتن مکمل منیزیم، مکمل های آنتی اکسیدانت و/یا ضد التهابی در طی 3 ماه قبل مداخله، گرفتن داروهای سرکوبگر ایمنی
    empty
    Intervention group: Magnesium supplements (21st Century Pharmaceutical Company, Arizona, USA), 250 mg, one capsule for 24 weeks orally. Control group: placebo (Barij Essence, Kashan, Iran), one capsule for 24 weeks orally.
    empty
    گروه مداخله: مکمل منیزیم (شرکت داروسازی قرن 21، آریزونا، آمریکا)، 250 میلی گرم، یک کپسول برای 24 هفته به صورت خوراکی. گروه کنترل: کپسول پلاسبو (باریج اسانس، کاشان، ایران)، یک کپسول برای 24 هفته به صورت خوراکی.
    empty
    Outcomes: Carotid intima-media thickness (primary outcome) and metabolic profiles (secondary outcomes) will be quantified at study baseline and end-of-trial.
    empty
    پيامدها: ضخامت انتیما-مدیای شریان کاروتید (پیامد اولیه) و پروفایل های متابولیک (پیامدهای ثانویه) در ابتدا و انتهای مداخله اندازه گیری خواهد شد.
  • General information

    1
    1
    1
    Diabetic hemodialysis patients
    Aged 18 to 80 years
    بیماران همودیالیزی دیابتیک
    سن 18 تا 80 سال
    Patients with inflammatory and malignant diseases
    Taking magnesium supplements, antioxidant and/or anti-inflammatory supplements within 3 months prior to enrollment in the study
    Taking immunosuppressive agents
    بیماران مبتلا به بیماری های بدخیم و التهابی
    گرفتن مکمل منیزیم، مکمل های آنتی اکسیدانت و/یا ضد التهابی در طی 3 ماه قبل مداخله
    گرفتن داروهای سرکوبگر ایمنی
    empty
    At study baseline and after stratification for pre-intervention BMI (<25 and ≥25 kg/m2) and age (<50 and ≥50 y), subjects will be randomly divided into two groups to receive supplement or placebo. Randomization will be done by the use of computer-generated random numbers.
    empty
    در ابتدای مطالعه و بعد از طبقه بندی بر اساس مقادیر پایه نمایه توده بدنی (<25 و ≥25 کیلوگرم بر متر مربع) و سن (<50 و ≥50)، افراد به طور تصادفی برای دریافت مکمل یاری و پلاسبو تخصیص داده می شوند. تصادفی سازی با استفاده از جدول اعداد تصادفی ایجاد شده توسط کامپیوتر انجام خواهد شد.
    empty
    Participants, investigators or the assessors of the outcomes are unaware of the study groups.
    empty
    شرکت کنندگان و هم محققان یا ارزیابان پیامد از تخصیص گروههای مطالعه بی اطلاعند.
    empty
    empty
  • Intervention groups

    #1
    Intervention group: 250 mg magnesium (Jalinous pharmaceutical Company, Tehran, Iran), daily for 24 weeks orally.
    Intervention group: 250 mg magnesium (21st Century Pharmaceutical Company, Arizona, USA), daily for 24 weeks orally.
    گروه مداخله: 250 میلی گرم منیزیم (شركت داروسازی جالینوس، تهران، ایران)، روزانه برای 24 هفته به صورت خوراکی.
    گروه مداخله: 250 میلی گرم منیزیم (شركت داروسازی قرن 21، آریزونا، آمریکا)، روزانه برای 24 هفته به صورت خوراکی.
  • Recruitment centers

    #1
    Name of recruitment center - English: Akhavan Clinic
    Name of recruitment center - Persian: کلینیک اخوان
    Full name of responsible person - English: Zatollah Asemi
    Full name of responsible person - Persian: ذات اله عاصمی
    Street address - English: Shahid Rajaee Avenue, Kashan
    Street address - Persian: کاشان، خیابان شهید رجایی
    City - English: Kashan
    City - Persian: کاشان
    Province:
    Country: Iran (Islamic Republic of)
    Postal code:
    Phone:
    Fax:
    Email:
    Web page address:
    Name of recruitment center - English: Yasrebi Clinic
    Name of recruitment center - Persian: کلینیک یثربی
    Full name of responsible person - English: Zatollah Asemi
    Full name of responsible person - Persian: ذات اله عاصمی
    Street address - English: Ghotbe Ravandi Boulevard, Kashan
    Street address - Persian: کاشان، بلوار قطب راوندی
    City - English: Kashan
    City - Persian: کاشان
    Province: Isfehan
    Country: Iran (Islamic Republic of)
    Postal code: 8115187159
    Phone: +98 31 4446 0180
    Fax:
    Email: asemi_r@yahoo.com
    Web page address:
  • Sponsors / Funding sources

    #1
    contact.organization_id:
    Name of organization / entity - English: Vice chancellor for research, Kashan University of Medical Sciences
    Name of organization / entity - Persian: معاونت پژوهشی دانشگاه علوم پزشکی کاشان
    Full name of responsible person - English: Gholamali Hamidi
    Full name of responsible person - Persian: غلامعلی حمیدی
    Street address - English: Ghotbe Ravandi Boulevard, Kashan
    Street address - Persian: کاشان، بلوار قطب راوندی
    City - English: Kashan
    City - Persian: کاشان
    Province:
    Country: Iran (Islamic Republic of)
    Postal code:
    Phone:
    Fax:
    Email:
    Web page address:

    Name of organization / entity - English:
    Name of organization / entity - Persian:
    Full name of responsible person - English: Gholamali Hamidi
    Full name of responsible person - Persian: غلامعلی حمیدی
    Street address - English: Ghotbe Ravandi Boulevard, Kashan
    Street address - Persian: کاشان، بلوار قطب راوندی
    City - English: Kashan
    City - Persian: کاشان
    Province: Isfehan
    Country: Iran (Islamic Republic of)
    Postal code: 8115187159
    Phone: +98 31 5554 2999
    Fax:
    Email: hamidi-gh@kaums.ac.ir
    Web page address:
    empty
    Public
    empty
    Domestic
    empty
    Academic
    Vice chancellor for research, Kashan University of Medical Sciences
    Kashan University of Medical Sciences
    معاونت پژوهشی دانشگاه علوم پزشکی کاشان
    دانشگاه علوم پزشکی کاشان
  • Person responsible for general inquiries

    contact.organization_id:
    Name of organization / entity - English: Kashan University of Medical Sciences
    Name of organization / entity - Persian: دانشگاه علوم پزشكي كاشان
    Full name of responsible person - English: Zatollah Asemi
    Full name of responsible person - Persian: ذات اله عاصمی
    Position - English: Ph.D of Nutrition
    Position - Persian: دکترای تغذیه
    Latest degree:
    Area of specialty/work: 0
    Area of specialty/work title - English:
    Area of specialty/work title - Persian:
    Street address - English: Ghotbe Ravandi Boulevard, Kashan
    Street address - Persian: کاشان، بلوار قطب راوندی
    City - English: Kashan
    City - Persian: کاشان
    Province:
    Province - English:
    Province - Persian:
    contact.provinces_available: 1
    Country: Iran (Islamic Republic of)
    Postal code:
    Phone: +98 31 5546 3378
    Mobile: +98 913 361 5446
    Fax:
    Email: asemi_z@kaums.ac.ir; asemi_r@yahoo.com
    Web page address:
    contact.organization_id:
    Name of organization / entity - English: Kashan University of Medical Sciences
    Name of organization / entity - Persian: دانشگاه علوم پزشكي كاشان
    Full name of responsible person - English: Zatollah Asemi
    Full name of responsible person - Persian: ذات اله عاصمی
    Position - English: Ph.D of Nutrition
    Position - Persian: دکترای تغذیه
    Latest degree: phd
    Area of specialty/work: 34
    Area of specialty/work title - English:
    Area of specialty/work title - Persian:
    Street address - English: Ghotbe Ravandi Boulevard, Kashan
    Street address - Persian: کاشان، بلوار قطب راوندی
    City - English: Kashan
    City - Persian: کاشان
    Province: Isfehan
    Province - English:
    Province - Persian:
    contact.provinces_available: 1
    Country: Iran (Islamic Republic of)
    Postal code: 8115187159
    Phone: +98 31 5546 3378
    Mobile: +98 913 361 5446
    Fax:
    Email: asemi_r@yahoo.com
    Web page address:
  • Person responsible for scientific inquiries

    contact.organization_id:
    Name of organization / entity - English: Kashan University of Medical Sciences
    Name of organization / entity - Persian: دانشگاه علوم پزشکی کاشان
    Full name of responsible person - English: Zatollah Asemi
    Full name of responsible person - Persian: ذات اله عاصمی
    Position - English: Ph.D of Nutrition
    Position - Persian: دکترای تغذیه
    Latest degree:
    Area of specialty/work: 0
    Area of specialty/work title - English:
    Area of specialty/work title - Persian:
    Street address - English: Ghotbe Ravandi Boulevard, Kashan
    Street address - Persian: کاشان، بلوار قطب راوندی
    City - English: Kashan
    City - Persian: کاشان
    Province:
    Province - English:
    Province - Persian:
    contact.provinces_available: 1
    Country: Iran (Islamic Republic of)
    Postal code:
    Phone: +98 31 5546 3378
    Mobile: +98 913 361 5446
    Fax:
    Email: asemi_z@kaums.ac.ir; asemi_r@yahoo.com
    Web page address:

    Name of organization / entity - English:
    Name of organization / entity - Persian:
    Full name of responsible person - English: Zatollah Asemi
    Full name of responsible person - Persian: ذات اله عاصمی
    Position - English: Ph.D of Nutrition
    Position - Persian: دکترای تغذیه
    Latest degree: phd
    Area of specialty/work: 34
    Area of specialty/work title - English:
    Area of specialty/work title - Persian:
    Street address - English: Ghotbe Ravandi Boulevard, Kashan
    Street address - Persian: کاشان، بلوار قطب راوندی
    City - English: Kashan
    City - Persian: کاشان
    Province: Isfehan
    Province - English:
    Province - Persian:
    contact.provinces_available: 1
    Country: Iran (Islamic Republic of)
    Postal code: 8115187159
    Phone: +98 31 5546 3378
    Mobile: +98 913 361 5446
    Fax:
    Email: asemi_r@yahoo.com
    Web page address:
  • Person responsible for updating data

    contact.organization_id:
    Name of organization / entity - English: Kashan University of Medical Sciences
    Name of organization / entity - Persian: دانشگاه علوم پزشکی کاشان
    Full name of responsible person - English: Zatollah Asemi
    Full name of responsible person - Persian: ذات اله عاصمی
    Position - English: Ph.D of Nutrition
    Position - Persian: دکترای تغذیه
    Latest degree:
    Area of specialty/work: 0
    Area of specialty/work title - English:
    Area of specialty/work title - Persian:
    Street address - English: Ghotbe Ravandi Boulevard, Kashan
    Street address - Persian: کاشان، بلوار قطب راوندی
    City - English: Kashan
    City - Persian: کاشان
    Province:
    Province - English:
    Province - Persian:
    contact.provinces_available: 1
    Country: Iran (Islamic Republic of)
    Postal code:
    Phone: +98 31 5546 3378
    Mobile: +98 913 361 5446
    Fax:
    Email: asemi_z@kaums.ac.ir; asemi_r@yahoo.com
    Web page address:

    Name of organization / entity - English:
    Name of organization / entity - Persian:
    Full name of responsible person - English: Zatollah Asemi
    Full name of responsible person - Persian: ذات اله عاصمی
    Position - English: Ph.D of Nutrition
    Position - Persian: دکترای تغذیه
    Latest degree: phd
    Area of specialty/work: 34
    Area of specialty/work title - English:
    Area of specialty/work title - Persian:
    Street address - English: Ghotbe Ravandi Boulevard, Kashan
    Street address - Persian: کاشان، بلوار قطب راوندی
    City - English: Kashan
    City - Persian: کاشان
    Province: Isfehan
    Province - English:
    Province - Persian:
    contact.provinces_available: 1
    Country: Iran (Islamic Republic of)
    Postal code: 8115187159
    Phone: +98 31 5546 3378
    Mobile: +98 913 361 5446
    Fax:
    Email: asemi_r@yahoo.com
    Web page address:
  • Sharing plan

    undecided
    undecided
    na
    undecided
    na
    na
    na
    empty
    Undecided - It is not yet known if there will be a plan to make this available.
    empty
    هنوز تصمیم نگرفته‌ام - برنامه انتشار آن هنوز مشخص نیست.

Protocol summary

Study aim
Objective: The aim of this study is to determine the effects of magnesium supplementation on carotid intima-media thickness (CIMT) and metabolic profiles in diabetic hemodialysis patients.
Design
Study design: randomized double-blind placebo-controlled trial. Randomization will be done by the use of computer-generated random numbers. Patients will be assigned into two groups to receive magnesium supplement (n=30) or placebo (n=30).
Settings and conduct
Among diabetic hemodialysis patients referred to Yasrebi Clinic affiliated to Kashan University of Medical Sciences, Kashan, Iran, 60 patients will be selected according to inclusion and exclusion criteria. Participants, investigators or the assessors of the outcomes are unaware of the study groups. Supplements and placebos are similar in shape and size. Fasting blood samples will be taken at baseline and 24 weeks after the intervention. At the beginning and the end of the intervention: 24 weeks.
Participants/Inclusion and exclusion criteria
Inclusion criteria: Diabetic hemodialysis patients aged 18 to 80 years will be included in the study.Exclusion criteria: Patients with inflammatory and malignant diseases, taking magnesium supplements, antioxidant and/or anti-inflammatory supplements within 3 months prior to enrollment in the study, taking immunosuppressive agents
Intervention groups
Intervention group: Magnesium supplements (21st Century Pharmaceutical Company, Arizona, USA), 250 mg, one capsule for 24 weeks orally. Control group: placebo (Barij Essence, Kashan, Iran), one capsule for 24 weeks orally.
Main outcome variables
Outcomes: Carotid intima-media thickness (primary outcome) and metabolic profiles (secondary outcomes) will be quantified at study baseline and end-of-trial.

General information

Reason for update
Acronym
IRCT registration information
IRCT registration number: IRCT2017090133941N19
Registration date: 2017-11-20, 1396/08/29
Registration timing: retrospective

Last update: 2019-09-19, 1398/06/28
Update count: 2
Registration date
2017-11-20, 1396/08/29
Registrant information
Name
Mohammadreza Sharif
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 31 5546 3378
Email address
ostadmohammadi-vr@kaums.ac.ir
Recruitment status
Recruitment complete
Funding source
Vice chancellor for research, Kashan University of Medical Sciences
Expected recruitment start date
2017-10-20, 1396/07/28
Expected recruitment end date
2017-11-03, 1396/08/12
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Clinical trial of the effect of magnesium supplementation compared with the placebo on carotid intima-media thickness and metabolic profiles in diabetic hemodialysis patients
Public title
Effect of magnesium supplementation in treatment of diabetic hemodialysis patients
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
Diabetic hemodialysis patients Aged 18 to 80 years
Exclusion criteria:
Patients with inflammatory and malignant diseases Taking magnesium supplements, antioxidant and/or anti-inflammatory supplements within 3 months prior to enrollment in the study Taking immunosuppressive agents
Age
From 18 years old to 80 years old
Gender
Both
Phase
2
Groups that have been masked
  • Participant
  • Investigator
  • Outcome assessor
Sample size
Target sample size: 60
Randomization (investigator's opinion)
Randomized
Randomization description
At study baseline and after stratification for pre-intervention BMI (<25 and ≥25 kg/m2) and age (<50 and ≥50 y), subjects will be randomly divided into two groups to receive supplement or placebo. Randomization will be done by the use of computer-generated random numbers.
Blinding (investigator's opinion)
Double blinded
Blinding description
Participants, investigators or the assessors of the outcomes are unaware of the study groups.
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Kashan University of Medical Sciences
Street address
Ghotbe Ravandi Boulevard, Kashan
City
Kashan
Province
Isfehan
Postal code
8115187159
Approval date
2017-10-19, 1396/07/27
Ethics committee reference number
IR.KAUMS.MEDNT.REC.1396.69

Health conditions studied

1

Description of health condition studied
Hemodialysis
ICD-10 code
N18
ICD-10 code description
Chronic kidney disease

Primary outcomes

1

Description
Mean left CIMT
Timepoint
At the beginning of the study and after 24 weeks of intervention
Method of measurement
Sonography

2

Description
Maximum left CIMT
Timepoint
At the beginning of the study and after 24 weeks of intervention
Method of measurement
Sonography

3

Description
Mean right CIMT
Timepoint
At the beginning of the study and after 24 weeks of intervention
Method of measurement
Sonography

4

Description
Maximum right CIMT
Timepoint
At the beginning of the study and after 24 weeks of intervention
Method of measurement
Sonography

Secondary outcomes

1

Description
Insulin
Timepoint
At the beginning of the study and after 24 weeks of intervention
Method of measurement
Elisa kit

2

Description
Insulin resistance
Timepoint
At the beginning of the study and after 24 weeks of intervention
Method of measurement
Calculation using HOMA formula

3

Description
Triglycerides
Timepoint
At the beginning of the study and after 24 weeks of intervention
Method of measurement
Enzymatic kit

4

Description
Total cholesterol
Timepoint
At the beginning of the study and after 24 weeks of intervention
Method of measurement
Enzymatic kit

5

Description
HDL
Timepoint
At the beginning of the study and after 24 weeks of intervention
Method of measurement
Enzymatic kit

6

Description
Hs-CRP
Timepoint
At the beginning of the study and after 24 weeks of intervention
Method of measurement
Elisa kit

7

Description
Nitric oxide
Timepoint
At the beginning of the study and after 24 weeks of intervention
Method of measurement
Spectrophotometry

8

Description
Malondialdehyde
Timepoint
At the beginning of the study and after 24 weeks of intervention
Method of measurement
Spectrophotometry

9

Description
Glutathione
Timepoint
At the beginning of the study and after 24 weeks of intervention
Method of measurement
Spectrophotometry

10

Description
Total antioxidant capacity
Timepoint
At the beginning of the study and after 24 weeks of intervention
Method of measurement
Spectrophotometry

Intervention groups

1

Description
Intervention group: 250 mg magnesium (21st Century Pharmaceutical Company, Arizona, USA), daily for 24 weeks orally.
Category
Treatment - Drugs

2

Description
Control group: Placebo (Barij Essence, Kashan, Iran), daily for 24 weeks orally.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Yasrebi Clinic
Full name of responsible person
Zatollah Asemi
Street address
Ghotbe Ravandi Boulevard, Kashan
City
Kashan
Province
Isfehan
Postal code
8115187159
Phone
+98 31 4446 0180
Email
asemi_r@yahoo.com

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Kashan University of Medical Sciences
Full name of responsible person
Gholamali Hamidi
Street address
Ghotbe Ravandi Boulevard, Kashan
City
Kashan
Province
Isfehan
Postal code
8115187159
Phone
+98 31 5554 2999
Email
hamidi-gh@kaums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Kashan University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Kashan University of Medical Sciences
Full name of responsible person
Zatollah Asemi
Position
Ph.D of Nutrition
Latest degree
Ph.D.
Other areas of specialty/work
Nutrition
Street address
Ghotbe Ravandi Boulevard, Kashan
City
Kashan
Province
Isfehan
Postal code
8115187159
Phone
+98 31 5546 3378
Fax
Email
asemi_r@yahoo.com
Web page address

Person responsible for scientific inquiries

Contact
Name of organization / entity
Kashan University of Medical Sciences
Full name of responsible person
Zatollah Asemi
Position
Ph.D of Nutrition
Latest degree
Ph.D.
Other areas of specialty/work
Nutrition
Street address
Ghotbe Ravandi Boulevard, Kashan
City
Kashan
Province
Isfehan
Postal code
8115187159
Phone
+98 31 5546 3378
Fax
Email
asemi_r@yahoo.com
Web page address

Person responsible for updating data

Contact
Name of organization / entity
Kashan University of Medical Sciences
Full name of responsible person
Zatollah Asemi
Position
Ph.D of Nutrition
Latest degree
Ph.D.
Other areas of specialty/work
Nutrition
Street address
Ghotbe Ravandi Boulevard, Kashan
City
Kashan
Province
Isfehan
Postal code
8115187159
Phone
+98 31 5546 3378
Fax
Email
asemi_r@yahoo.com
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
Not applicable
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Not applicable
Analytic Code
Not applicable
Data Dictionary
Not applicable
Loading...